Kelly CRISPR & Gene Editing Technology ETF is a ETF series of Strategic Trust (series S000073961). Net assets $2.6M as of 2023-11-30. Index fund.
Showing 15 of 25 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| CRISPR Therapeutics AG | — | $380K | 1470.22% |
| Beam Therapeutics Inc | — | $346K | 1336.15% |
| Thermo Fisher Scientific Inc | — | $257K | 992.98% |
| Intellia Therapeutics Inc | — | $226K | 872.57% |
| Prime Medicine Inc | — | $156K | 604.84% |
| Editas Medicine Inc | — | $152K | 586.56% |
| Caribou Biosciences Inc | — | $128K | 494.44% |
| Verve Therapeutics Inc | — | $112K | 434.77% |
| Poseida Therapeutics Inc | — | $111K | 427.54% |
| AbbVie Inc | — | $104K | 400.82% |
| Sanofi SA | — | $85K | 328.10% |
| Novartis AG | — | $79K | 307.35% |
| Allogene Therapeutics Inc | — | $78K | 299.84% |
| Agilent Technologies Inc | — | $73K | 283.65% |
| 2seventy bio Inc | — | $45K | 174.95% |
| Report date | Net assets |
|---|---|
| 2023-11-30 | $2.6M |
| 2023-08-31 | $2.4M |
| 2023-05-31 | $2.5M |
| 2023-02-28 | $2.6M |
| 2022-11-30 | $4.0M |
| 2022-08-31 | $5.3M |
| 2022-05-31 | $973K |
| 2022-02-28 | $1.3M |